Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up.
Barakat RR, Sabbatini P, Bhaskaran D, Revzin M, Smith A, Venkatraman E, Aghajanian C, Hensley M, Soignet S, Brown C, Soslow R, Markman M, Hoskins WJ, Spriggs D. Barakat RR, et al. Among authors: sabbatini p. J Clin Oncol. 2002 Feb 1;20(3):694-8. doi: 10.1200/JCO.2002.20.3.694. J Clin Oncol. 2002. PMID: 11821450
Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K. Sabbatini P, et al. Clin Cancer Res. 2006 Sep 15;12(18):5503-10. doi: 10.1158/1078-0432.CCR-05-2670. Clin Cancer Res. 2006. PMID: 17000686 Clinical Trial.
Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
Sabbatini PJ, Ragupathi G, Hood C, Aghajanian CA, Juretzka M, Iasonos A, Hensley ML, Spassova MK, Ouerfelli O, Spriggs DR, Tew WP, Konner J, Clausen H, Abu Rustum N, Dansihefsky SJ, Livingston PO. Sabbatini PJ, et al. Clin Cancer Res. 2007 Jul 15;13(14):4170-7. doi: 10.1158/1078-0432.CCR-06-2949. Clin Cancer Res. 2007. PMID: 17634545
Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission.
Diefenbach CS, Gnjatic S, Sabbatini P, Aghajanian C, Hensley ML, Spriggs DR, Iasonos A, Lee H, Dupont B, Pezzulli S, Jungbluth AA, Old LJ, Dupont J. Diefenbach CS, et al. Among authors: sabbatini p. Clin Cancer Res. 2008 May 1;14(9):2740-8. doi: 10.1158/1078-0432.CCR-07-4619. Clin Cancer Res. 2008. PMID: 18451240 Clinical Trial.
Abagovomab for ovarian cancer.
Pfisterer J, Harter P, Simonelli C, Peters M, Berek J, Sabbatini P, du Bois A. Pfisterer J, et al. Among authors: sabbatini p. Expert Opin Biol Ther. 2011 Mar;11(3):395-403. doi: 10.1517/14712598.2011.553598. Epub 2011 Jan 18. Expert Opin Biol Ther. 2011. PMID: 21241213 Review.
Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients.
Sabbatini P, Tsuji T, Ferran L, Ritter E, Sedrak C, Tuballes K, Jungbluth AA, Ritter G, Aghajanian C, Bell-McGuinn K, Hensley ML, Konner J, Tew W, Spriggs DR, Hoffman EW, Venhaus R, Pan L, Salazar AM, Diefenbach CM, Old LJ, Gnjatic S. Sabbatini P, et al. Clin Cancer Res. 2012 Dec 1;18(23):6497-508. doi: 10.1158/1078-0432.CCR-12-2189. Epub 2012 Oct 2. Clin Cancer Res. 2012. PMID: 23032745 Clinical Trial.
211 results